—— About 68Ga-LNC1007 Injection ——
01
68Ga-LNC1007 injection is a radionuclide diagnostic drug used for dual integrin αvβ3 and fibroblast activation protein (FAP)-targeted imaging in adult patients with solid tumors.
02
FAP is a type II integral membrane glycoprotein that is highly expressed in cancer-associated fibroblasts (CAF) of most cancer types, including gastric cancer, esophageal cancer, lung cancer, colorectal cancer, ovarian cancer, etc., and with limited expression on normal fibroblasts. Integrins are significantly upregulated in angiogenic endothelial cells and most types of tumor cells but absent in resting endothelial cells of normal tissues and play an important role in regulating tumor growth, angiogenesis, local invasiveness, and metastatic potential. Integrin αvβ3, a critical family member of integrins, can be used by CAFs to induce and assemble an FN-rich matrix and trigger cancer cell directional invasion and migration. These characteristics make αvβ3 a suitable target for tumor imaging and therapy.
03
68Ga-LNC1007 injection with dual targeting of FAP and αvβ3 can significantly improve the efficiency of tumor diagnosis. Recent studies (pre-clinical studies and IITs) have shown that 68Ga-FAPI had a high uptake and image contrast in PET/CT imaging of solid tumors such as pancreatic cancer, esophageal cancer, non-small cell lung cancer, head and neck cancer, colon cancer, breast cancer, cholangiocarcinoma, and lung cancer. The high and selective tumor uptake may open new applications for noninvasive tumor characterization, staging examinations, or radioligand therapy.
LNC was jointly founded by DC PHARMA and Professor Chen Xiaoyuan, a top expert in molecular imaging and nanomedicine, in 2021. Adhering to the concept of "Innovation-driven Micro Radiotheranostics R&D, Benefit People from Precision Therapy", LNC is focusing on the construction of a globally leading integrated diagnosis and therapy innovation platform on cancer nuclear medicine R&D. Next, LNC will continue to rely on DC PHARMA's strong and sound production and research system for the entire nuclear medicine industry chain, strengthen innovation, providing precision diagnosis and therapeutic methods for cancer patients and promoting the development of nuclear medicine in the world.
